

Financial and Non-Financial Highlights

Mitsubishi Tanabe Pharma Corporation and consolidated subsidiaries

	(Billions of yen)			(% Change)
	FY 2016	FY 2017 ¹	FY 2018	FY 2017/2018
Revenue	423.9	433.8	424.7	-2.1
Core operating profit	94.5	78.5	55.8	-28.9
Operating profit	94.0	77.2	50.3	-34.9
Profit attributable to owners of the Company	71.2	57.9	37.3	-35.5
R&D expenses	64.7	79.0	86.5	+9.4
Capital expenditures ²	14.4	6.0	8.5	+41.7
Total assets	984.5	1,048.4	1,056.2	+0.7
Total equity	871.4	894.8	910.3	+1.7
Net cash provided by operating activities	59.7	66.9	41.4	-
Net cash used in investing activities	-10.5	-19.1	-31.2	-
Net cash used in financing activities	-24.4	-32.5	-25.8	-

	(%)		
Financial indicators			
Overseas revenue ratio	24.4	26.0	27.6
Operating margin	22.2	17.8	11.8
R&D expenses ratio	15.3	18.2	20.4
Ratio of equity attributable to owners of the Company to total assets	87.4	84.2	85.0
ROE	8.5	6.6	4.2
Dividend payout ratio	40.9	63.9	84.0

	(Yen)			(%)
Per share amounts				
Profit attributable to owners of the Company	127.03	103.35	66.64	-35.5
Cash dividends	52.00	66.00 ³	56.00	-

	(%)			
Cost of sales				
Number of employees	7,280	7,187	7,228	+0.6
Number of clinical trials started ⁴	4	6	3	-
CO ₂ emissions ⁵ (Thousands of tons-CO ₂)	102	96	91	-5.9
Water Withdrawal (Thousand m ³)	7,980	5,375	4,913	-8.6
Waste Generation (Domestic) (t)	5,936	12,230	5,768	-52.8
Final waste disposal rate (Domestic) (%)	0.33	0.37	0.59	-

1. MTPC has finalized the purchase price allocation in connection with the acquisition of NeuroDerm Ltd. during the first six months of the fiscal year ending March 31, 2019. Hence, a retroactive adjustment of the comparative amount for previous fiscal year listed in Condensed Consolidated Statements of Financial Position was made.

2. Property, plant and equipment and intangible assets on an accrual basis.

3. In commemoration of the 10th anniversary of its founding, the Company paid a commemorative dividend of ¥10 per share in fiscal 2017.

4. Phase 2 clinical trials and thereafter. Including in-licensed products.

5. Domestic and overseas production and research bases, and offices (the amount of fuel used in sales vehicles is not included in the total).


For further information about financial data, please refer to "10-Year Financial Summary." [← Page 61](#)

Note: Figures before fiscal 2014 are based on Japanese GAAP.


Revenue / Operating margin




Operating profit / R&D expenses




Profit attributable to owners of the Company / ROE



Total assets / Ratio of equity attributable to owners of the Company to total assets



Cash dividends per share / Dividend payout ratio



Number of employees



* In commemoration of the 10th anniversary of its founding, the Company implemented a commemorative dividend of ¥10 per share in fiscal 2017.